{"disease":{"id":"mycosis-fungoides-mf","name":"mycosis fungoides mf"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02580552","title":"Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"miRagen Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04218825","title":"REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT01579318","title":"Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OncoSec Medical Incorporated","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}